Loading...
RFL logo

Rafael Holdings, Inc.NYSE:RFL Stock Report

Market Cap US$116.0m
Share Price
n/a
1Y7.2%
7D-29.2%
1D-1.8%
Portfolio Value
​
View

Rafael Holdings, Inc.

NYSE:RFL Stock Report

Market Cap: US$116.0m

Rafael Holdings (RFL) Stock Overview

Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. More details

RFL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($980K)

Volatile share price over the past 3 months compared to the US market


RFL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW492,272 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
492,272 investors already sharing narratives
View all narratives

Rafael Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rafael Holdings
Historical stock prices
Current Share PriceUS$2.23
52 Week HighUS$3.96
52 Week LowUS$1.12
Beta0.29
1 Month Change-0.45%
3 Month Change84.30%
1 Year Change7.21%
3 Year Change6.19%
5 Year Change-95.97%
Change since IPO-54.49%

Recent News & Updates

Seeking Alpha • Jun 29

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Summary Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 29

Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever

Summary Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out. Read the full article on Seeking Alpha
Analysis Article • Mar 26

Does Rafael Holdings (NYSE:RFL) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Oct 11

Does Rafael Holdings (NYSE:RFL) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 21

Solid Earnings May Not Tell The Whole Story For Rafael Holdings (NYSE:RFL)

Rafael Holdings, Inc.'s ( NYSE:RFL ) healthy profit numbers didn't contain any surprises for investors. We think this...
Analysis Article • Aug 04

We Think Rafael Holdings (NYSE:RFL) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 13

Rafael Holdings GAAP EPS of -$0.22

Rafael Holdings press release (NYSE:RFL): FQ1 GAAP EPS of -$0.22 (vs. -$5.88 Y/Y). As of Oct. 31, the company had cash, cash equivalents and marketable securities of $93.8M, which includes $33M in net proceeds from the sale of real estate assets on Aug. 22.
Seeking Alpha • Nov 16

Rafael stepping back from early-stage development in favor of acquisition, licensing

Rafael Holdings (NYSE:RFL) is putting the brakes on its early-stage development programs as part of an effort to reduce spending and instead focus on investing in, acquiring, or in-licensing clinical-stage candidates. CEO Bill Conkling said that by doing so, Rafael (RFL) has the "potential to achieve meaningful clinical milestones, which if successful, could improve the lives of patients and increase value for our shareholders." As of July 31, the Company had cash, cash equivalents and marketable securities of $63.2M, and then an additional $33M in net proceeds from the sale of real estate assets on August 23. The stock is down ~63% year to date.
Analysis Article • Jan 20

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Nov 18

Rafael Holdings: A Coin Flip

RFL has a large bet on one drug for cancer treatment. This important bet just recently failed to succeed as a treatment for one type of cancer, with other studies ongoing. Aside from some real estate side income, RH is a generic biotech coin flip.
Seeking Alpha • Jun 21

Rafael Holdings announces merger with Rafael Pharmaceuticals

Zhanna Hapanovich/iStock via Getty Images Rafael Holdings (RFL) has added ~7.4% in the premarket after announcing a merger agreement with Rafael Pharmaceuticals, a private-owned late-stage oncology company in which the former and its subsidiaries has a majority stake. The president and CEO of Rafael Pharmaceuticals Sanjeev Luther will join the board of directors of the combined company which will be led by Ameet Mallik as the CEO and Howard Jonas as the chairman. The merged company will retain the name of Rafael
Analysis Article • Jan 25

What You Need To Know About Rafael Holdings, Inc.'s (NYSE:RFL) Investor Composition

A look at the shareholders of Rafael Holdings, Inc. ( NYSE:RFL ) can tell us which group is most powerful. Institutions...
Analysis Article • Dec 01

The Rafael Holdings (NYSE:RFL) Share Price Has Gained 29% And Shareholders Are Hoping For More

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

Shareholder Returns

RFLUS PharmaceuticalsUS Market
7D-29.2%-2.0%0.8%
1Y7.2%44.2%20.6%

Return vs Industry: RFL underperformed the US Pharmaceuticals industry which returned 44.2% over the past year.

Return vs Market: RFL underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is RFL's price volatile compared to industry and market?
RFL volatility
RFL Average Weekly Movement15.0%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: RFL's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RFL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201722Howard Jonaswww.rafaelholdings.com

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

Rafael Holdings, Inc. Fundamentals Summary

How do Rafael Holdings's earnings and revenue compare to its market cap?
RFL fundamental statistics
Market capUS$115.96m
Earnings (TTM)-US$32.55m
Revenue (TTM)US$980.00k
118.3x
P/S Ratio
-3.6x
P/E Ratio

Is RFL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RFL income statement (TTM)
RevenueUS$980.00k
Cost of RevenueUS$48.00k
Gross ProfitUS$932.00k
Other ExpensesUS$33.49m
Earnings-US$32.55m

Last Reported Earnings

Apr 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin95.10%
Net Profit Margin-3,321.73%
Debt/Equity Ratio0.8%

How did RFL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 13:47
End of Day Share Price 2026/07/10 00:00
Earnings2026/04/30
Annual Earnings2025/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rafael Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.